Workshop programme

Artificial intelligence (AI) and big data

AI imaging for clinical decision support
Alexios Antonopoulos, Greece
Potential of big data to improve ASCVD prediction in women
Maryam Kavousi, The Netherlands

Atherosclerosis and liver disease

New links between atherogenic dyslipidemia and metabolic dysfunction-associated steatotic liver disease
Joel Haas, France
New isights from Hypobetalipoproteinemia
Salvatore Petta, Italy

Dealing with inflammation in ASCVD prevention

Paul Ridker , USA
Ulrich Laufs, Germany

Diet and Life style in ASCVD prevention

What is the rationale for the dietary recommendations for fat intake?
Jacob J. Christensen , Norway
Physical activity and ASCVD prevention: is there a dose response curve?
Signe Sørensen Torekov , Norway

Familial hypercholesterolemia (FH) from screening to management

Monogenic vs polygenic hyperchol
Jacqueline S. Dron, USA
How should we screen - systematic vs. Cascade
Tomas Freiberger, Czechia

Identifying high risk patient by imaging

Universal screening in primary prevention?
Marc Dweck, UK
How does SCORE2 perform in different parts of Europe and in different sub-groups?
Emanuele Di Angelantonio, UK

Immunity and atherosclerosis

Interplay of lipoproteins with the immune response
Christoph Binder, Austria
Lipid receptors shaping immune cell functions in atherosclerosis
Sabine Steffens, Germany

Lipid risk factors beyond LDL

Lipoprotein(a): molecular mechanisms involved in athero-thrombosis
Gilles Lambert , France
Women and ASCVD
Lale Tokgözoğlu, Turkey

Molecular mechanisms of plaque evolution

Mechanisms of plaque progression/regression
Minna Kaikkonen- Määttä, Finland
Specific roles for PI3Ks in mechanotransduction during atherosclerosis
Muriel Laffargue, France

Obesity and cardiometabolic disease

Connecting gut hormones and lipid metabolism
Niina Matikainen, Finland
Bariatric surgery and lipids
Geltrude Milgrone, Italy

Precision medicine and ASCVD

"Primordial" prevention
Nisreen A Alwan, UK
Consequences of Gender Transition on ASCVD risk: a clinical perspective
Asa Tivesten, Sweden

Primary dyslipidaemia - new molecular targets on production and clearance

New insights in the genetics of FH
Mafalda Bourbon, Portugal
Genetics of FH in FH registry: an urgent need for an extensive cleaning
Alain Carrie, France

The INTERASPIRE registry - variation in care

How do TG levels vary in CVD across WHO regions
Peter Libby, USA
How do traditional lipids and Lp(a) differ in CVD patients across WHO regions
Kausik Ray, UK
Measures of Glycaemia in CVD- How do they differ across regions
Lars Rydén, Sweden
Characteristics of patients with CAD across WHO regions
David Wood, Ireland

The role of the vessel wall in atherosclerosis

Extracellular matrix
Thorsten Kessler, Germany
Fibroblast diversity in atherosclerosis
Judith Sluimer, The Netherlands

Triglyceride hydrolysis

The role of ANGPTL8 in the regulation of triglyceride metabolism
Robert Konrad, USA
Lipoprotein lipase: How can an unstable enzyme orchestrate intravascular lipolysis?
Michael Ploug, Denmark